Medicare AdvantageCoverageMedium impact
MA08.029c, Natalizumab (Tysabri®) and Related Biosimilars
Independence Blue Cross·Neurology·Pharmacy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Summary
The Medicare Advantage policy MA08.029c for Natalizumab (Tysabri®) and Related Biosimilars has been reissued and will take effect April 2, 2025. This is a pharmacy policy update that may affect coverage or authorization requirements for this multiple sclerosis medication.
Action Required
By April 2, 2025: Billing and pharmacy teams should review the updated MA08.029c policy for any changes to prior authorization requirements, coverage criteria, or billing procedures for Natalizumab (Tysabri®) and related biosimilars for Medicare Advantage patients. Access the full policy details at the source URL to identify specific workflow changes needed.